NewEdge Wealth LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

NewEdge Wealth LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,719 shares of the biopharmaceutical company's stock after purchasing an additional 4,287 shares during the period. NewEdge Wealth LLC's holdings in Regeneron Pharmaceuticals were worth $28,737,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. FMR LLC raised its position in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company's stock valued at $8,098,661,000 after buying an additional 669,517 shares in the last quarter. Northern Trust Corp lifted its stake in Regeneron Pharmaceuticals by 3.3% during the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company's stock worth $878,271,000 after purchasing an additional 34,326 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company's stock worth $799,061,000 after purchasing an additional 25,792 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Regeneron Pharmaceuticals by 0.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company's stock valued at $796,142,000 after purchasing an additional 2,666 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $697,296,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.7 %

Regeneron Pharmaceuticals stock traded down $15.62 during trading hours on Friday, hitting $904.70. 665,264 shares of the stock traded hands, compared to its average volume of 491,976. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The firm's 50-day moving average price is $958.37 and its two-hundred day moving average price is $888.22. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The company has a market cap of $99.30 billion, a PE ratio of 26.48, a PEG ratio of 2.73 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm's revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company posted $10.96 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company's stock, valued at $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company's stock, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Joseph L. Goldstein sold 2,707 shares of the business's stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the transaction, the director now directly owns 6,382 shares of the company's stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock valued at $13,124,641 in the last three months. 8.83% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on REGN shares. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 13th. Barclays lifted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 23rd. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an "outperform" rating and a $1,125.00 price target for the company. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an "outperform" rating in a research note on Monday, February 5th. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, January 5th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $970.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.